Anh Dam Tran, Rory Chen, Grant Sara, Rebecca McKetin
{"title":"澳大利亚甲基苯丙胺使用者的医疗保健费用。","authors":"Anh Dam Tran, Rory Chen, Grant Sara, Rebecca McKetin","doi":"10.1111/dar.14043","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>This study aims to estimate the drug treatment costs and health services utilisation costs among people who used different treatment modalities to treat methamphetamine dependence.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This is a sub-study of a prospective observational cohort study MATES (<i>n</i> = 501), including recruitment from 15 residential rehabilitation services, 13 counselling services and 11 detoxification units in Sydney and Brisbane, Australia. Participants with methamphetamine dependence who had used methamphetamine in the 28 days before baseline assessment and completed 3- and 12-month follow-ups were included (<i>n</i> = 323). Unit costs per day/episode of each treatment type were taken from published literature. Self-reported health services utilisation (HSU) was collected via structured face-to-face and telephone interviews. Hospital admissions were allocated a likely diagnosis grouping from the Australian Refined Diagnosis-Related Groupings. Emergency department presentations were allocated a likely triage category.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Average drug treatment costs per person per year were AU$10,540 (SD 13,995), accounting for 63% of total health-care costs, which were AU$16,862 (SD 19,908). Drug treatment costs of counselling participants were only around 40% of detox and residential rehab participants. However, the HSU costs of detox and rehab participants were approximately 60% lower than those of counselling participants.</p>\n </section>\n \n <section>\n \n <h3> Discussion and Conclusions</h3>\n \n <p>Drug treatment costs accounted for more than half of total health care costs, representing a substantial financial burden. Detox and rehab treatment costs more but saved costs in health services use. HSU costs among people who had severe mental health problems and injected methamphetamine were substantially high. Strategies to support these groups are necessary to reduce the cost burden.</p>\n </section>\n </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"44 4","pages":"1157-1168"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.14043","citationCount":"0","resultStr":"{\"title\":\"Health-care costs among people who use methamphetamine in Australia\",\"authors\":\"Anh Dam Tran, Rory Chen, Grant Sara, Rebecca McKetin\",\"doi\":\"10.1111/dar.14043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>This study aims to estimate the drug treatment costs and health services utilisation costs among people who used different treatment modalities to treat methamphetamine dependence.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This is a sub-study of a prospective observational cohort study MATES (<i>n</i> = 501), including recruitment from 15 residential rehabilitation services, 13 counselling services and 11 detoxification units in Sydney and Brisbane, Australia. Participants with methamphetamine dependence who had used methamphetamine in the 28 days before baseline assessment and completed 3- and 12-month follow-ups were included (<i>n</i> = 323). Unit costs per day/episode of each treatment type were taken from published literature. Self-reported health services utilisation (HSU) was collected via structured face-to-face and telephone interviews. Hospital admissions were allocated a likely diagnosis grouping from the Australian Refined Diagnosis-Related Groupings. Emergency department presentations were allocated a likely triage category.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Average drug treatment costs per person per year were AU$10,540 (SD 13,995), accounting for 63% of total health-care costs, which were AU$16,862 (SD 19,908). Drug treatment costs of counselling participants were only around 40% of detox and residential rehab participants. However, the HSU costs of detox and rehab participants were approximately 60% lower than those of counselling participants.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Discussion and Conclusions</h3>\\n \\n <p>Drug treatment costs accounted for more than half of total health care costs, representing a substantial financial burden. Detox and rehab treatment costs more but saved costs in health services use. HSU costs among people who had severe mental health problems and injected methamphetamine were substantially high. Strategies to support these groups are necessary to reduce the cost burden.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11318,\"journal\":{\"name\":\"Drug and alcohol review\",\"volume\":\"44 4\",\"pages\":\"1157-1168\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.14043\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug and alcohol review\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/dar.14043\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol review","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dar.14043","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
Health-care costs among people who use methamphetamine in Australia
Introduction
This study aims to estimate the drug treatment costs and health services utilisation costs among people who used different treatment modalities to treat methamphetamine dependence.
Methods
This is a sub-study of a prospective observational cohort study MATES (n = 501), including recruitment from 15 residential rehabilitation services, 13 counselling services and 11 detoxification units in Sydney and Brisbane, Australia. Participants with methamphetamine dependence who had used methamphetamine in the 28 days before baseline assessment and completed 3- and 12-month follow-ups were included (n = 323). Unit costs per day/episode of each treatment type were taken from published literature. Self-reported health services utilisation (HSU) was collected via structured face-to-face and telephone interviews. Hospital admissions were allocated a likely diagnosis grouping from the Australian Refined Diagnosis-Related Groupings. Emergency department presentations were allocated a likely triage category.
Results
Average drug treatment costs per person per year were AU$10,540 (SD 13,995), accounting for 63% of total health-care costs, which were AU$16,862 (SD 19,908). Drug treatment costs of counselling participants were only around 40% of detox and residential rehab participants. However, the HSU costs of detox and rehab participants were approximately 60% lower than those of counselling participants.
Discussion and Conclusions
Drug treatment costs accounted for more than half of total health care costs, representing a substantial financial burden. Detox and rehab treatment costs more but saved costs in health services use. HSU costs among people who had severe mental health problems and injected methamphetamine were substantially high. Strategies to support these groups are necessary to reduce the cost burden.
期刊介绍:
Drug and Alcohol Review is an international meeting ground for the views, expertise and experience of all those involved in studying alcohol, tobacco and drug problems. Contributors to the Journal examine and report on alcohol and drug use from a wide range of clinical, biomedical, epidemiological, psychological and sociological perspectives. Drug and Alcohol Review particularly encourages the submission of papers which have a harm reduction perspective. However, all philosophies will find a place in the Journal: the principal criterion for publication of papers is their quality.